Standout Papers

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation 2017 2026 2020 2023 2.1k
  1. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (2017)
    Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine
  2. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (2019)
    Mark E. Robson, Nadine Tung et al. Annals of Oncology

Immediate Impact

7 from Science/Nature 72 standout
Sub-graph 1 of 20

Citing Papers

Transient loss of Polycomb components induces an epigenetic cancer fate
2024 StandoutNature
PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends
2024 Standout
2 intermediate papers

Works of Sarah Runswick being referenced

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout

Author Peers

Author Last Decade Papers Cites
Sarah Runswick 2227 889 798 1227 18 2.9k
Wenting Wu 2581 1691 817 1437 20 3.8k
John Zevenhoven 2182 601 459 2614 23 4.1k
Carrie A. Adelman 1401 1344 361 1524 29 2.9k
Zhigang C. Wang 1846 473 530 2544 22 3.8k
Miguel Martín 1432 629 570 726 15 1.8k
Maarit Bärlund 2188 716 661 3114 26 4.9k
Rita K. Schmutzler 2648 524 1305 2464 48 4.0k
Bethan Powell 1616 332 698 1776 10 2.9k
Ellen Wientjens 1740 233 759 2424 17 3.3k
Rachel Brough 2016 333 475 2302 39 3.0k

All Works

Loading papers...

Rankless by CCL
2026